H7 angel syndicate invests in life science and medtech companies from seed to pre-IPO through deal-specific opportunities.

The H7 Accelerator provides a 12-week, equity-free program for healthcare companies at the Angel to Series A stages, featuring Life Science and Medtech tracks in Silicon Valley.

1633 Old Bayshore Hwy, Burlingame, CA, USA

The M7 Demo Day showcases 11 finalists from the M7 Healthcare Acceleration Program, bringing together investors, physicians, clinicians, and entrepreneurs from around the world.

M7 Healthcare Accelerator and eChinaHealth co-host a Healthcare Investment Conference during the J.P. Morgan 41st Annual Healthcare Conference on January 9, 2023. The event includes back-to-back conferences, an evening reception, and a healthcare startup roadshow.

Dr. Sophie Lin has joined H7 BioCapital as a Partner.

H7 BioCapital is a global venture platform supporting healthcare companies through accelerator programs, venture capital financing, and strategic events to connect investors, scientists, and entrepreneurs.

Janna Bednenko is a PhD scientist with 15 years of experience in drug discovery, specializing in expression and purification of drug targets like ion channels, transporters, and GPCRs. She previously led protein expression at AbCellera.

Jeewoo (Jenny) Kang is a graduate student at Stanford University applying synthetic biology to neuroscience tools. She developed the RELEASE platform and is engineering the rabies virus for cell-type specificity.

Robin is a PhD candidate at Rice University researching therapeutic modalities for infections using catalytic mRNAs. He has participated in entrepreneurial programs like Rice Launchpad and NSF I-Corps.

The H7 Accelerator Program 2023 Cohort offers opportunities for startups to grow.

H7 BioCapital, headquartered in Silicon Valley, invests in life science and medtech, fostering innovation through accelerator programs and strategic partnerships.